CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Monoclonal antibody targeting mono- or poly-glycylated tubulin

Référence

02645-01

Statut des brevets

“not patented”

Inventeurs

Marie Hélène BRE
Anne AUBUSSON-FLEURY
Nicolette LEVILLIERS

Statut commercial

Non-exclusive licenses

Laboratoire

CNRS, Université Paris Sud (Paris XI) UMR 8080 « Développement et Evolution », France, http://www.umr8080.u-psud.fr/umr.html

Description

CONTEXT

Microtubules (MTs) are essential components of the cytoskeleton. Subpopulations of MTs can be differentially marked by several highly conserved post-translational modifications (PTMs). These PTMs are particularly abundant in ciliary and flagellar axonemal MTs. Cilium and flagellum are ubiquitous cellular extensions which are essential not only for motility (in protozoa, sperm, respiratory epithelia, brain ventricules…) but also for ensuring sensory functions during development and normal physiology (photoreceptors, olfactory cells, renal cells, neuronal cells…). The laboratory has focused on biochemical characterization of tubulin, and has discovered in Paramecium, a post-translational modification (PTM): polyglycylation (published in Science 1994). Thanks to antibodies developed in the laboratory, AXO 49 and TAP 952, this PTM has been shown to be highly conserved over evolution, ranging from the single cell, like protozoa, to humans. Polyglycylation occurs mainly, if not exclusively, in cell types that have cilia and flagella.

TECHNICAL DESCRIPTION

The invention consists in two hybridomas producing two monoclonal antibodies targeting, in several cell types and organisms, a post-translational modification (PTM) of tubulin: glycylation. TAP 952 targets mono-glycylated tubulin (lateral connecting branch of 1 glycine unit on the C-terminal sequence of tubulin) and AXO 49 targets polyglycylated tubulin (lateral connecting branch of a polymer of at least 3 glycines). The validity of the epitope recognized by the antibodies has been assessed by testing their specificities on synthetic peptides having a sequence identical to the C-terminal sequence of Paramecium tubulin, on which glycin polymers of various lengths are branched.


Double immunolabeling of axonemal microtubules of lemur (a,b,c) and human (d,e,f) spermatozoa with an anti-tubulin sequence polyclonal antibody (red in a and d) and AXO 49 (green in b and e), and single staining with TAP 952 (green in c and f). DNA was labeled with Hoechst. Bar.

BENEFITS

These two antibodies are immunological tools for the visualization of polyglycylation in cilia from various cell types (cf figure).
They are the only antibodies available for this specific PTM of tubulin. Commercial anti-tubulin antibodies are targeting a sequence of tubulin, that means they target all tubulin isotypes in the cell or in the tissue. For example, among a wide panel of microtubules, like in brain, AXO 49 and TAP 952 can be used for detecting specifically the presence of cilia. Other commercial antibodies target other tubulin PTMs like acetylation, detyrosination or phosphorylation.

INDUSTRIAL APPLICATIONS

AXO 49 and TAP 952 have applications either for tubulin functional studies or for health related research (ciliopathies, morphogenesis). They have already been used in various cells, organisms and tissues : Paramecium, Giarda, oviduct, trachea, olfactory and nasal epithelium, vestibular tissues, neuronal cells, spermatozoïds…
New applications of these tools will arise as, recently, other proteins than tubulin have been shown to be glycylated.

For further information, please contact us (Ref 02645-01)

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents